Market Research Report
Generalized Myasthenia Gravis (gMG) - Market Insights, Epidemiology, and Market Forecast-2028
|Published by||DelveInsight Business Research LLP||Product code||905938|
|Published||Content info||215 Pages
Delivery time: 1-2 business days
|Generalized Myasthenia Gravis (gMG) - Market Insights, Epidemiology, and Market Forecast-2028|
|Published: August 1, 2019||Content info: 215 Pages||
DelveInsight's 'Generalized Myasthenia Gravis (gMG)-Market Insights, Epidemiology, and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of gMG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted market size of Generalized Myasthenia Gravis (gMG) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Study Period: 2017-2028
The DelveInsight's Generalized Myasthenia Gravis (gMG) market report gives a thorough understanding of the Myasthenia Gravis by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myasthenia Gravis in the US, Europe, and Japan.
The Generalized Myasthenia Gravis (gMG) epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Generalized Myasthenia Gravis (gMG) in the 7MM. The epidemiology is segmented by total diagnosed prevalent cases, auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK) and Japan from 2017-2028.
According to DelveInsight, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017. The estimates suggest a higher diagnosed prevalence of gMG in the United States with 32,188 cases in 2017. Among EU5, Spain had the highest diagnosed prevalent population of Gmg, whereas France had the lowest cases.
This segment of the Generalized Myasthenia Gravis (gMG) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of Generalized Myasthenia Gravis (gMG) is mainly accounted by symptomatic treatments comprising acetylcholinesterase Inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and procedures (thymectomy).
Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies, it has significantly impacted the market size of Myasthenia Gravis after its launch.
The Generalized Myasthenia Gravis (gMG) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Generalized Myasthenia Gravis in 7MM was found to be USD 2,602 million in 2017. The United States accounts for the largest market size of Generalized Myasthenia Gravis, in comparison to EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
This market is further expected to grow during the forecasted period of 2019-2028 owing to the launch of upcoming therapies. Detailed chapter for upcoming therapies, like Rozanolixizumab (UCB Pharma); CFZ533 (Novartis); Efgartigimod (Argenx); Zilucoplan (Ra Pharmaceuticals); Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); Ravulizumab (Alexion Pharmaceuticals); IMVT-1401 (Immunovant); M281 (Momenta Pharmaceuticals); CV-MGO1(CuraVac), and others have also been covered in the report, are expected to enter the MG market by 2028. The market is further divided based on the available and upcoming drugs in to first and second-line of therapies.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.